% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

  • jrus2010 jrus2010 Feb 16, 2011 12:54 PM Flag

    First cycle approvals for standard BLAs

    Is anyone aware of companies (mid-cap and below) that have gotten first cycle approvals on a standard review BLA application? I haven't found any notable approvals which is concerning.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I am guessing he works for PFE, paid cash to a bank in the Caymans. PFE would love to keep the price down before a buyout offer. Sorry just gotta play the conspiracy card. LOL. Cheers.

    • To clarify:

      In 2003 the FDA transferred some of the therapeutic biological products that had been reviewed and regulated by the Center for Biologics Evaluation and Research (CBER) to the Center for Drug Evaluation and Research (CDER).

      Categories of biological products transferred to CDER (meaning companies file an NDA for such products):

      >Monoclonal antibodies for in vivo use.

      >Proteins intended for therapeutic use, including cytokines, enzymes, and other novel proteins except for those that are specifically assigned to CBER (e.g., vaccines and blood products). This category includes therapeutic proteins derived from plants, animals, or microorganisms, and recombinant versions of these products.

      >Immunomodulators: proteins or peptides that are not antigen specific that are intended to treat disease by inhibiting or modifying a pre-exisiting immune response; and proteins or peptides intended to act in antigen-specific fashion to treat or prevent autoimmune diseases by inhibiting or modifying pre-existing immune responses.

      >Growth factors, cytokines, and monoclonal antibodies intended to mobilize, stimulate, decrease or otherwise alter the production of cells in vivo. This category includes growth factors, cytokines, and monoclonal antibodies, as well as non-biological agents, administered as mobilizing agents for their direct therapeutic effect on the recipient, as well as growth factors, cytokines, and monoclonal antibodies administered for the purpose of subsequently harvesting the mobilized, stimulated, decreased or otherwise altered cells for use in a human cellular or tissue-based product.

      Categories of Biological Products Remaining in CBER (meaning companies trying to get such products still file a BLA):

      >Cellular products, including products composed of human, bacterial or animal cells, or from physical parts of those cells (such as whole cells, cell fragments, or other components intended for use as preventative or therapeutic vaccines).

      >Gene therapy products. Human gene therapy/gene transfer is the administration of nucleic acids, viruses, or genetically engineered microorganisms that mediate their effect by transcription and/or translation of the transferred genetic material, and/or by integrating into the host genome. Cells may be modified in these ways ex vivo for subsequent administration to the recipient, or altered in vivo by gene therapy products administered directly to the recipient.

      >Vaccines and vaccine-associated products: products, regardless of their composition or method of manufacture, intended to induce or enhance a specific immune response to prevent or treat a disease or condition, or to enhance the activity of other therapeutic interventions.

      >Allergenic extracts used for the diagnosis and treatment of allergic diseases and allergen patch tests.

      >Antitoxins, antivenins, and venoms.

      >Blood, blood components, plasma derived products, including recombinant and transgenic versions of plasma derivatives, blood substitutes, plasma volume expanders, human or animal polyclonal antibody preparations including radiolabeled or conjugated forms, and certain fibrinolytics such as plasma-derived plasmin, and red cell reagents.

      >Human cells, tissues and cellular and tissue-based products. This category includes cells that have been harvested following in vivo administration of a CDER-regulated growth factor, cytokine, or monoclonal antibody, as well as those requiring ex vivo manipulation.

0.838+0.008(+0.96%)Apr 28 4:00 PMEDT